* BIOLASE Inc BIOL.OQ BIOL.O is expected to show a rise
in
quarterly revenue when it reports results on March 15.
* The Foothill Ranch California-based company is expected
to
report a 13.4% increase in revenue to $14.068 million from
$12.41 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. The company's guidance on
January 18 2023, for the period ended December 31, was for
revenue between $14.00 million and $14.40 million.
* Refinitiv's mean analyst estimate for BIOLASE Inc is for
a loss
of 64 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for BIOLASE Inc
is
$3.5, above its last closing price of $0.43.
The company's guidance on May 12 2022 for the period ended
December 31 was for gross profit margin between USD50% and
USD52%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.85 -0.84 -1.10 Missed -30.4
Jun. 30 2022 -0.64 -0.62 -0.91 Missed -46.2
Mar. 31 2022 -0.79 -0.68 -0.81 Missed -19.1
Dec. 31 2021 -0.62 -0.75 Missed -20
Sep. -0.62 -0.69 -0.50 Beat 27.3
30 2021
Jun. 30 2021 -1.13 -1.08 -0.50 Beat 53.8
Mar. 31 2021 -1.25 -1.25 -1.50 Missed -20
Dec. 31 2020 -1.00 -0.92 -1.75 Missed -90.9
This summary was machine generated March 13 at 20:58 GMT. All
figures in US dollars unless otherwise stated